JP2007269750A - Insulin resistance-improving action composition, adiponectin-increasing action composition, hemoglobin a1c-improving action composition, blood glucose level-improving action composition, uric acid value-decreasing action composition, hepatic function-improving action composition, abdominal girth value-decreasing action composition and body weight-decreasing action composition - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a composition having an insulin resistance-improving action and the like. <P>SOLUTION: This composition is a Gentianella alborosea (Gilg) Fabris extract powder tablet containing the powder of an extract obtained from the Gentianella alborosea (Gilg) Fabris. The Gentianella alborosea (Gilg) Fabris extract powder tablet has an insulin resistance-improving action, an adiponectin-increasing action, a hemoglobin A1c-improving action and a blood glucose level-improving action. The Gentianella alborosea (Gilg) Fabris extract powder tablet has furthermore a uric acid value-decreasing action, a hepatic function-improving action, an abdominal girth value-decreasing action and a body weight-decreasing action. <P>COPYRIGHT: (C)2008,JPO&INPIT

Description

  The present invention relates to an insulin resistance improving composition, an adiponectin increasing action composition, a hemoglobin A1c improving action composition, a blood glucose level improving action composition, a uric acid level reducing action composition, at least containing elcampure and elcampure extract. The present invention relates to a function improving action composition, an abdominal circumference reducing action composition, and a weight reducing action composition.

  Traditionally, El Campure is a perennial dicotyledonous plant that grows in the highlands of the Andes region of South America, Peru, and has been taken as a traditional medicinal herb since the pre-Inca period.

In recent years, this El Campure has been known to have a preventive and ameliorating action on lifestyle-related diseases such as an antihypertensive action, a bad cholesterol reducing action, a good cholesterol raising action, an anti-diabetic effect, an anti-obesity effect, etc. (See Patent Document 1).
JP 2004-172 A

  However, as described above, about the insulin resistance improving action, adiponectin increasing action, hemoglobin A1c improving action, blood sugar level improving action, uric acid level reducing action, liver function improving action, abdominal circumference reducing action and body weight reducing action etc. It still has the problem that it has not been clearly elucidated.

  The present invention has been made in view of the above points, and includes an insulin resistance improving action, an adiponectin increasing action, a hemoglobin A1c improving action, a blood glucose level improving action, a uric acid value reducing action, a liver function improving action, an abdominal circumference value reducing action and It aims at providing the composition which has a weight reduction effect | action.

  The composition for improving insulin resistance according to claim 1 contains at least one of elcampure and an extract of elcampule and has an insulin resistance improving action.

  The composition for increasing adiponectin according to claim 2 contains at least one of elcampure and an extract of elcampule and has an adiponectin increasing action.

  The composition for improving hemoglobin A1c according to claim 3 contains at least one of elcampure and an extract of elcampule and has a hemoglobin A1c improving action.

  The blood glucose level improving composition according to claim 4 contains at least one of Elcampure and an extract of Elcampule and has a blood glucose level improving action.

  The composition for reducing uric acid level according to claim 5 contains at least one of ercampure and an extract of ercampule and has a uric acid level reducing action.

  The composition for improving liver function according to claim 6 contains at least one of elcampure and an extract of elcampule and has an effect of improving liver function.

  The composition for reducing abdominal circumference value according to claim 7 contains at least one of elcampure and an extract of elcampule and has an abdominal circumference value reducing action.

  The composition for reducing body weight according to claim 8 contains at least one of ercampure and an extract of ercampure and has a weight-reducing action.

  According to the composition for improving insulin resistance according to claim 1, since it contains at least one of elcampure and an extract of elcampule, an insulin resistance improving action can be expected.

  According to the composition for increasing adiponectin according to claim 2, since it contains at least one of ercampure and an extract of ercampure, an adiponectin increasing action can be expected.

  According to the composition for improving hemoglobin A1c according to claim 3, since it contains at least one of ercampure and an extract of ercampule, it can be expected to improve hemoglobin A1c.

  According to the blood glucose level improving composition according to claim 4, since it contains at least one of Elcampure and Elcampure extract, it can be expected to improve blood glucose level.

  According to the composition for reducing uric acid level according to claim 5, since it contains at least one of ercampure and an extract of ercampule, an uric acid level reducing action can be expected.

  According to the composition for improving liver function according to claim 6, since it contains at least one of elcampure and an extract of elcampule, an effect of improving liver function can be expected.

  According to the composition for reducing the abdominal circumference according to claim 7, since it contains at least one of Elcampure and an extract of Elcampule, an abdominal circumference reducing action can be expected.

  According to the composition for reducing body weight according to claim 8, since it contains at least one of ercampure and an extract of ercampure, it can be expected to have a weight-reducing effect.

  Hereinafter, the composition for improving insulin resistance according to one embodiment of the present invention will be described.

  First, the composition for improving insulin resistance has an action for stabilizing blood pressure and an action for improving insulin resistance. Here, the insulin is a kind of hormone secreted from the human pancreas, and has an action of lowering blood sugar level by promoting sugar uptake by the muscles and liver and accumulating as an energy source. Insulin resistance is a state in which this insulin action is reduced, that is, a state in which the blood insulin level is rising, and by improving this insulin resistance, blood glucose level in the blood is improved, obesity and It has the effect of improving or preventing metabolic syndrome-related items such as lipoprotein abnormalities, high blood pressure, and high blood sugar.

  Moreover, this insulin resistance improving action composition has an adiponectin increasing action. Here, this adiponectin is a secreted protein secreted by adipocytes itself. By increasing this adiponectin, metabolic syndrome related items such as obesity, lipoprotein abnormalities, high blood pressure, and high blood sugar are improved. Or it has the effect of preventing.

  Furthermore, this insulin resistance improving action composition has a hemoglobin A1c (HbA1c) improving action. Here, the hemoglobin A1c is an adult-type hemoglobin and a glycated hemoglobin to which glucose is bound, and by improving the numerical value of the hemoglobin A1c, heart disease, stroke, neuropathy, renal failure, etc. It is a protein that can reduce the risk of complications.

  Moreover, this insulin resistance improving action composition has a blood sugar level improving action which is an action of improving blood sugar level in blood. Here, this blood sugar level means that if this blood sugar level becomes too low, headaches, dizziness, and blurred vision appear, and if this blood sugar level becomes too high, it can cause diabetes and It adversely affects various organs and may cause arteriosclerosis.

  Furthermore, this insulin resistance improving action composition has a uric acid level decreasing action, which is an action of decreasing the uric acid level in the blood. And this uric acid is the final metabolite of purine, and when the concentration of uric acid in the blood increases, uric acid that cannot be dissolved in the blood may crystallize, causing gout and arteriosclerosis. Is.

  The composition for improving insulin resistance has a γ-GTP (gamma-glutamyl transpeptidase) reducing action. Here, this γ-GTP is also referred to as γ-GP, and is an enzyme that serves as an index of alcoholic liver damage. By increasing the γ-GTP level in blood, acute hepatitis, chronic hepatitis, cirrhosis, It may cause liver cancer, biliary tract disease, pancreatic cancer and the like.

  Furthermore, this insulin resistance improving action composition has an ALT decreasing action, which is an action of reducing the ALT (alanine aminotransferase) level in blood. Here, this ALT is generally called GPT (glutamic pyruvate transaminase), and is an aminotransferase having pyridoxal phosphate as a coenzyme. Hepatitis, viral hepatitis, drug-induced hepatic disorder, alcoholic hepatitis, chronic hepatitis, liver cancer, cirrhosis, liver stagnation, obstructive jaundice, etc. may occur.

  Moreover, this insulin resistance improving action composition has the effect | action which reduces AST (aspartate aminotransferase). Here, this AST is also called GOT (Glutamic-oxaloacetic transaminase), and when the AST value in the blood increases, liver diseases such as acute, chronic hepatitis, fatty liver, There is a risk of heart disease such as myocardial infarction.

  Therefore, since this insulin resistance improving composition has a γ-GTP reducing action and an ALT and AST reducing action, it has a liver function improving action.

  In addition, this insulin resistance-improving composition has an effect of decreasing the abdominal circumference value, which is an effect of reducing the value of the human abdominal circumference, and also has an effect of reducing the weight of the human body. ing. In other words, since this composition for improving insulin resistance has an effect of reducing abdominal circumference and weight, it has the effect of improving or preventing metabolic syndrome-related items such as obesity, lipoprotein abnormalities, high blood pressure, and hyperglycemia. is doing.

  Therefore, this insulin resistance improving composition has an anti-visceral fat obesity action since it has an abdominal circumference value reducing action and a body weight reducing action.

  In addition, this insulin resistance improving composition has an action of decreasing the total cholesterol level in blood and an action of increasing HDL cholesterol (good cholesterol) in blood. In addition, this insulin resistance-improving composition has the effect of reducing the neutral fat level in the blood, and the value of free fatty acid (non-esterified fatty acid NEFA (free-fatty acid)) in the blood is appropriate. It has the effect of making it a proper value. Furthermore, this insulin resistance improving action composition has an action of lowering the neutral fat level in the blood to an appropriate value by lowering the neutral fat level in the blood.

  Therefore, this insulin resistance-improving composition improves the metabolic syndrome-related items such as obesity, lipoprotein abnormalities, high blood pressure, and hyperglycemia because it has the effect of adjusting the neutral fat level in the blood to an appropriate value. Or it has the effect of preventing.

  The composition for improving insulin resistance contains at least one of Elcampure (Gentianella alborosea (Gilg) Fabris) and Elcampure extract as a main component. Here, this El Campure is a dicotyledonous, gentian, and perennial plant belonging to the genus Genus, and inhabits a cold plateau called Puna at an altitude of 3500 m to 4000 m in the Andes region of Peru, South America.

  Further, this elcampure is a 5-fold amount of water-containing alcohol in the dry whole grass (roots, stems and leaves) of this elcampule, for example, 30% to 90%, preferably 50% to 80%, for example 70% alcohol. It is contained in the composition for improving insulin resistance as an elcampure extract that is spray-dried after adding dextrin to the elcampure solution that has been soaked and extracted. Here, this El Campule extract is an El Campule extract powder as a so-called El Campule extract powder, which is rich in xanthone derivatives. Further, this El Campule extract can be extracted by adding water of, for example, 50 ° C. or more and 100 ° C. or less, preferably 80 ° C. or more, instead of the alcohol.

  And as this insulin resistance improving action composition, it can also be used as a functional food, cosmetics, topical skin or medicine containing this insulin resistance improving action composition. Therefore, as this insulin resistance improving action composition, it can also be suitably used as a skin external preparation, a functional food, a pharmaceutical, and a cosmetic. For this reason, this insulin resistance improving composition is characterized in that it contains at least an Elcampure extract and has an insulin resistance improving action, and is used for lowering blood sugar levels in blood. It is used as food / drinks, pharmaceuticals, cosmetics, etc. with an indication of the effect.

  The form for providing this insulin resistance-improving composition may be powder, granule, powder, tablet, dragee, capsule, liquid, or syrup. It may be shaped. Examples of the excipient and diluent used include gelatin, saccharides, starches, fatty acids and salts thereof, fats and oils, talc, physiological saline, and other masking agents. These may be taken as they are, but it is also convenient to take them mixed with foods such as various dishes, confectionery and candy.

  Here, when the composition for improving insulin resistance is used as a food or drink, there is no risk of harm to human health, and in normal social life, it is taken by oral or gastrointestinal administration, It is not restricted to food categories, pharmaceutical products, quasi drugs, etc. in administrative categories, but includes a wide range of, for example, general foods, health foods, health functional foods, beauty foods, quasi drugs or pharmaceuticals taken orally. Including.

  In addition, as foods and drinks using the composition for improving insulin resistance, beverages (including concentrated concentrates and adjustment powders) such as soft drinks, carbonated drinks, nutritional drinks, fruit drinks, and lactic acid drinks, tequila, liqueur, Alcoholic beverages such as wine, shochu, beer, and sake, frozen desserts such as ice cream, ice sherbet, shaved ice, noodles such as buckwheat, udon, harsame, gyoza skin, cucumber skin, Chinese noodles, instant noodles, rice cakes, chewing gum, Candy, gum, chocolate, tablet confectionery, snack confectionery, biscuits, jelly, jam, cream, baked confectionery, and other fishery products such as kamaboko, ham, sausage, dairy products such as processed milk and fermented milk, salad oil, Tempura oil, margarine, mayonnaise, shortening, whipped cream, dressing, etc. Fats and oils and processed foods, seasonings such as sauces and sauces, soups, stews, salads, prepared dishes, pickles, various other forms of health and nutritional supplements, capsules such as tablets, hard capsules or soft capsules, drinks, granules It can be easily eaten and consumed by processing into a shape such as, and can be used in a wide range.

  Furthermore, when this insulin resistance improving composition is used as a cosmetic, for example, an ointment, a pap, a cream, an emulsion, a lotion, a pack, a jelly, a lip, a bath, a bath, a hair shampoo, a hair rinse, a hair tonic, Hair liquids, hair lotions, pomades, astringents, liquid soaps, solid soaps, body shampoos, etc. are preferred, and those that are used on the skin are preferred. Compositions that improve insulin resistance by absorption into the skin, scalp, etc. Various effects of the product are exhibited. Moreover, when this insulin resistance improving composition is used as a pharmaceutical, it can be used as a skin preparation, an internal solution, an internal solid preparation, an injection, a suppository, or the like.

  The composition for improving insulin resistance of the present invention is suitably applied to humans, but can also be applied to animals other than humans as long as the respective effects are exhibited. .

  On the other hand, the metabolic syndrome in which this composition for improving insulin resistance has the effect of preventing or improving related items is also called metabolic syndrome as a risk factor accumulation state which is a so-called metabolic syndrome. Furthermore, this metabolic syndrome is also called syndrome X, the deadly quartet, or multiple risk factor clustering.

  The metabolic syndrome refers to a state having a plurality of lifestyle-related diseases that promote arteriosclerosis, that is, a state suffering from a complex lifestyle-related disease. In addition, a person with metabolic syndrome has an extremely high risk of progression of arteriosclerosis, and as a result, cerebral infarction, angina pectoris, and myocardial infarction are likely to occur. The metabolic syndrome is premised on obesity as a related item, and means three or more cases including obesity among obesity, lipoprotein abnormality, high blood pressure and hyperglycemia.

  Furthermore, obesity refers to a case where the waist circumference around the height of the navel is 85 cm or more in the case of men and 90 cm or more in the case of women. Lipoprotein abnormality refers to a state corresponding to at least one of a case where the neutral fat (TG) value is 150 mg / dl or more and a case where the HDL cholesterol value is less than 40 mg / dl. Further, the high blood pressure value refers to a case where the systolic blood pressure is 130 mmHg or more and the diastolic blood pressure is 85 mmHg or more. Hyperglycemia refers to a case where the fasting blood glucose level is 110 mg / dl or more, which is a boundary type.

  Next, an example of the effect of ingestion of Elcampure extract powder on the human body will be described.

(Test food)
First, as a test food, an Elcampule extract powder tablet (PREMIEX (registered trademark) Elcampure extract powder tablet: H tablet) in which about 150 mg of Elcampure extract powder was blended in one tablet was used.

(Test subjects)
The subjects of the study were those who had a healthy daily life and were in the metabolic syndrome related items in the medical examination, and some items were in the vicinity of the border and were not receiving any medication.

  Specifically, the test food intake group in which about 10 tablets of males and 8 tablets of women were ingested about H tablets per day was defined as the first intake group, and a total of 16 subjects, 11 males and 5 females, were subjects. It was. In addition, the test food intake group in which about 3 tablets each of male and female were ingested H tablets per day was designated as the second intake group, and 10 males, 7 males and 3 females, were used as the second intake group.

  Each test was conducted in compliance with the ethical principles and test plan based on the Declaration of Helsinki. Furthermore, for each of these subjects, the study contents, methods, and expected side effects were fully explained, and the test was conducted after exchanging written consent with each subject's free will.

(Study schedule and intake method)
First, regarding the test schedule, the non-intake period was 4 weeks as the pre-observation period, the intake period was 12 weeks (about 3 months), and the non-intake period was 4 weeks as the post-observation period.

  Regarding the method of taking H tablets, in the first intake group, H tablets are 10 tablets for men per day and 8 tablets for women, and in the second intake group, H tablets are 3 for both men and women per day. The tablets were taken in two doses, 30 minutes after breakfast and 30 minutes after dinner. Further, the subjects in each group were not changed in daily life such as eating habits, smoking and exercise as before the intake except for taking H tablets daily. However, the intake of health functional foods such as supplements such as isoflavones and vitamin C other than H tablets during the blood collection period was prohibited.

(Measuring method)
Then, the measurement date and blood collection date of each subject are set to 4 weeks before the start of intake (first time), immediately before the start of intake (second time), 2 weeks after the start of intake (third time), 4 weeks after the start of intake (fourth time), 6 weeks after the start of intake (5th), 8 weeks after the start of intake (6th), 12 weeks after the start of intake (7th), 2 weeks after the end of the intake period (8th), and 4 weeks after the end of the intake period The total was 9 times later (9th).

  Furthermore, as these measurement items, biochemical items such as AST (GOT), ALT (GPT), γ-GTP (γ-GT), total cholesterol, HDL cholesterol, neutral fat, free fatty acid, uric acid, blood glucose, hemoglobin A1c The other items were insulin and adiponectin.

  Here, as the systolic blood pressure, an appropriate value was less than 130 [mmHg]. As the diastolic blood pressure, an appropriate value was less than 85 [mmHg]. Furthermore, as an abdominal circumference, an appropriate value was less than 85 [cm] for men and less than 90 [cm] for women.

  Moreover, as AST (GOT), 10 [IU / L / 37 degreeC] or more and 40 [IU / L / 37 degreeC] or less were made into the appropriate value. Further, as ALT (GPT), an appropriate value is 5 [IU / L / 37 ° C.] or more and 40 [IU / L / 37 ° C.] or less. As γ-GTP (γ-GT), appropriate values were 70 [IU / L / 37 ° C. or lower] for men and 30 [IU / L / 37 ° C. or lower] for women.

  Furthermore, as total cholesterol, 150 [mg / dL] or more and 219 [mg / dL] or less were set as appropriate values. As HDL cholesterol, 40 [mg / dL] to 86 [mg / dL] for men and 40 [mg / dL] to 96 [mg / dL] for women were appropriate values.

  And as neutral fat, 50 [mg / dL] or more and 149 [mg / dL] or less were made into the appropriate value. Moreover, as a free fatty acid, 0.14 [mEq / L] or more and 0.85 [mEq / L] or less were made into the appropriate value. Furthermore, as uric acid, 3.7 [mg / dL] or more and 7.0 [mg / dL] or less for men and 2.5 [mg / dL] or more and 7.0 [mg / dL] or less for women, respectively, are appropriate. Value.

  Moreover, as blood glucose, 70 [mg / dL] or more and 109 [mg / dL] or less was made into the appropriate value. Furthermore, as hemoglobin A1c, 4.3 [%] or more and 5.8 [%] or less was made into the appropriate value. Furthermore, the proper value of insulin was 3.06 [μU / mL] to 16.9 [μU / mL].

  Next, the experimental results in the above example will be described.

  In the experiment of the above example, no subject dropped out after taking each group of H tablets and for some reason due to ingestion.

(First intake group)
First, Tables 1 to 16 show the results of the subjects A to P in the first intake group.

  Further, Table 17 shows the results of the measurement results for each subject shown in Tables 1 to 16 summarized for each item. At this time, the number of subjects who deviated from the appropriate value of each item was symptomatic, the number of subjects who improved by comparing the first and seventh times, and the number of subjects who improved by comparing the second and seventh times Each of the numbers includes the number of subjects who were within the range of appropriate values from before taking H tablets.

  As a result, as shown in Table 17, when the first time and the seventh time were compared, the decrease in the weight of 11 subjects, that is, the improvement was confirmed, and the second time and the seventh time were compared. The improvement of the name was confirmed, and when these were averaged, the improvement of 10.5 was confirmed.

  As for blood pressure, the first and seventh systolic blood pressures were compared, and as a result, displacement of 13 subjects' systolic blood pressures to an appropriate value, that is, improvement was confirmed, and the second and seventh times were compared. However, the improvement of 15 subjects was confirmed, and when these were averaged, the improvement of 14.0 people was confirmed. Furthermore, in this systolic blood pressure, 12 out of 16 subjects had symptoms that were outside the range of the appropriate value, and 12 of these subjects were able to confirm improvement once, and both improvements were confirmed There were eleven subjects. Therefore, in this systolic blood pressure, 100% of the subjects were symptomatic and improved once, and 91.7% were symptomatic and improved twice.

  Furthermore, when comparing the first and seventh diastolic blood pressures, it was confirmed that 14 subjects were able to confirm the displacement of the diastolic blood pressure to an appropriate value, that is, the improvement, and the second and seventh times were compared. The improvement of 13.0 persons was confirmed when these were averaged. Furthermore, in this diastolic blood pressure, 13 of 16 subjects had symptoms that were outside the range of the appropriate value, and 12 of these subjects confirmed improvement once, and both improvements were confirmed There were eleven subjects. Therefore, in this diastolic blood pressure, 92.3% of subjects had symptoms and improved once, and 84.6% of subjects had symptoms and improved twice.

  Next, in the abdominal circumference, when the first and seventh times are compared, the decrease in the abdominal circumference value of 9 subjects, that is, the improvement can be confirmed, and when the second and seventh times are compared, the improvement of 10 subjects can be confirmed. On average, 9.5 improvement was confirmed. Furthermore, in this abdominal circumference, 14 subjects out of 16 subjects have symptoms higher than the appropriate value, and among these subjects, 10 subjects have confirmed improvement once, and those who have confirmed improvement twice. There were seven people. Therefore, in this abdominal circumference, 71.4% of the subjects had symptoms and improved once, and 50.0% of the subjects had symptoms and improved twice.

  Moreover, in AST (GOT), when the 1st time and the 7th time were compared, the decrease of the AST (GOT) value in the blood of 12 subjects, that is, the improvement was confirmed, and when the 2nd time and the 7th time were compared, the subjects The improvement of 10 people was confirmed, and when these were averaged, the improvement of 11.0 people was confirmed. Furthermore, in this AST (GOT), 2 out of 16 subjects have symptoms higher than the appropriate value, and 2 of these subjects have confirmed the improvement once, and the improvement can be confirmed both. There was one subject. Therefore, in this AST (GOT), 100.0% of subjects had symptoms and improved once, and 50.0% of subjects had symptoms and improved twice.

  In ALT (GPT), when the first time and the seventh time were compared, a decrease in ALT (GPT) value in the blood of 11 subjects, that is, an improvement could be confirmed, and when the second time and the seventh time were compared, the subjects Improvement of 10 people could be confirmed, and when these were averaged, improvement of 10.5 people could be confirmed. Furthermore, in this ALT (GPT), 7 out of 16 subjects had symptoms higher than the appropriate value, and 5 of these subjects were able to confirm improvement once, and both improvements could be confirmed. There were 4 subjects. Therefore, in this ALT (GPT), 71.4% of the subjects had symptoms and improved once, and 57.1% of the subjects had symptoms and improved twice.

  Next, in γ-GTP (γ-GT), the first time and the seventh time were compared. As a result, a decrease in γ-GTP (γ-GT) value in the blood of 10 subjects, that is, an improvement was confirmed. When compared with the 7th time, the improvement of 10 subjects was confirmed, and when these were averaged, the improvement of 10.0 people was confirmed. Furthermore, in this γ-GTP (γ-GT), 9 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, 6 subjects confirmed improvement once, and the improvement was 2 Four subjects were able to confirm both times. Therefore, in this γ-GTP (γ-GT), 66.7% of the subjects had symptoms and improved once, and 44.4% of the subjects had symptoms and improved twice.

  Moreover, in the total cholesterol, when the 1st time and the 7th time were compared, the reduction | decrease of the total cholesterol level in the blood of 10 test subjects, ie, improvement was confirmed, and when the 2nd time and the 7th time were compared, 11 test subjects were improved. As a result, an average of 10.5 people was confirmed. Furthermore, in this total cholesterol, 8 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, there were 5 subjects who confirmed improvement once, and subjects who confirmed improvement twice. There were 4 people. Therefore, in this total cholesterol, 62.5% of subjects had symptoms and improved once, and 50.0% of subjects had symptoms and improved twice.

  As for HDL cholesterol, when the first time and the seventh time are compared, an increase in HDL cholesterol level in the blood of four subjects, that is, an improvement can be confirmed, and when the second time and the seventh time are compared, the improvement of five subjects As a result, an average of 4.5 people improved. Furthermore, with this HDL cholesterol, one subject out of 16 subjects has symptoms lower than the appropriate value, and one subject who has confirmed improvement once among these subjects, and a subject who has confirmed both improvements twice There were 0 people. Therefore, in this HDL cholesterol, 100.0% of subjects had symptoms and improved once, and 0.0% of subjects had symptoms and improved twice.

  Next, in the case of triglycerides, the first time and the seventh time were compared, and the decrease in the neutral fat level in the blood of 8 subjects, that is, the improvement was confirmed, and the second time and the seventh time were compared. Improvement was confirmed, and when these were averaged, an improvement of 7.0 was confirmed. Furthermore, in this triglyceride, 9 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, 7 subjects confirmed improvement once, and both improvements were confirmed twice. There were 3 subjects. Therefore, in this neutral fat, 77.8% of subjects had symptoms and improved once, and 33.3% of subjects had symptoms and improved twice.

  In the case of free fatty acids, when the first time and the seventh time were compared, the decrease in free fatty acid level in the blood of 9 subjects, that is, the improvement was confirmed, and when the second time and the seventh time were compared, the improvement of 8 subjects As a result, an average of 8.5 people improved. Furthermore, with this free fatty acid, 4 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, there were 3 subjects who confirmed improvement once, and subjects who confirmed improvement twice. There were two people. Therefore, with this free fatty acid, 75.0% of subjects had symptoms and improved once, and 50.0% of subjects had symptoms and improved twice.

  In the case of uric acid, when the first time and the seventh time are compared, the decrease or improvement of the uric acid level in the blood of 12 subjects can be confirmed, and when the second time and the seventh time are compared, the improvement of the seven subjects is confirmed. On average, 9.5 improvement was confirmed. Furthermore, in this uric acid, 4 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, there were 3 subjects who confirmed improvement once, and subjects who confirmed improvement twice. One person. Therefore, with this uric acid, 75.0% of subjects had symptoms and improved once, and 25.0% of subjects had symptoms and improved twice.

  Next, in the case of blood glucose, when comparing the first time and the seventh time, it was confirmed that the blood glucose level in the blood of 13 subjects was changed to an appropriate value, that is, improved, and when comparing the second time and the seventh time, 9 subjects were compared. The improvement of 11.0 persons was confirmed when these were averaged. Furthermore, in this blood glucose, 5 subjects out of 16 subjects have symptoms higher than the appropriate value, and among these subjects, 4 subjects have confirmed improvement once, and subjects who have confirmed improvement twice. There were four people. Therefore, in this blood glucose, 80.0% of subjects had symptoms and improved once, and 80.0% of subjects had symptoms and improved twice.

  Moreover, in hemoglobin A1c, when the 1st time and the 7th time are compared, the improvement of hemoglobin A1c value in the blood of 7 subjects can be confirmed, and when the 2nd time and 7th time are compared, the improvement of 7 subjects can be confirmed. When these were averaged, an improvement of 7.0 was confirmed. Furthermore, in this hemoglobin A1c, 5 out of 16 subjects had symptoms higher than the appropriate value, and among these subjects, 3 subjects confirmed improvement once, and subjects who confirmed improvement twice. There were three people. Therefore, in this blood glucose hemoglobin A1c, 60.0% of subjects had symptoms and improved once, and 60.0% of subjects had symptoms and improved twice.

  In the case of insulin, when the first time and the seventh time are compared, the decrease in insulin level in the blood of 9 subjects, that is, the improvement of resistance can be confirmed, and when the second time and the seventh time are compared, The improvement was confirmed, and when these were averaged, the improvement of 9.0 people was confirmed. Further, in this insulin, 5 out of 16 subjects have symptoms higher than the appropriate value, and among these subjects, 5 subjects have confirmed improvement once, and those who have confirmed improvement twice. One person. Therefore, in this insulin, 100.0% of subjects had symptoms and improved once, and 20.0% of subjects had symptoms and improved twice.

  Furthermore, in the case of adiponectin, when the second time and the seventh time were compared, an increase in the adiponectin level in the blood of 10 subjects, that is, an improvement was confirmed.

(Second intake group)
Next, Tables 18 to 27 show the results of the subjects a to j in the second intake group.

  Further, Table 28 shows the results of the measurement results for each subject shown in Tables 18 to 27 summarized for each item. At this time, the number of subjects who deviated from the appropriate value of each item was symptomatic, the number of subjects who improved by comparing the first and seventh times, and the number of subjects who improved by comparing the second and seventh times Each of the numbers includes the number of subjects who were within the range of appropriate values from before taking H tablets.

  As a result, as shown in Table 28, when comparing the first time and the seventh time, the improvement of the five subjects was confirmed, and when comparing the second time and the seventh time, the improvement of the three subjects was confirmed. On average, it was confirmed that 4.0 people improved.

  As for blood pressure, when comparing the first and the seventh with systolic blood pressure, the improvement of the systolic blood pressure of the four subjects can be confirmed, and when comparing the second and seventh times, the improvement of the five subjects is confirmed. It can be confirmed, and when these are averaged, an improvement of 4.5 people can be confirmed. Furthermore, in this systolic blood pressure, 5 out of 10 subjects have symptoms outside the range of the appropriate value, and among these subjects, 4 subjects have confirmed improvement once, and both improvements have been confirmed twice Three subjects were able to complete. Therefore, in this systolic blood pressure, 80.0% of the subjects had symptoms and improved once, and 60.1% of the subjects had symptoms and improved twice.

  Furthermore, when comparing the first and seventh diastolic blood pressure, the improvement of diastolic blood pressure of four subjects can be confirmed, and when comparing the second and seventh times, improvement of five subjects can be confirmed. On average, an improvement of 4.5 people was confirmed. Furthermore, in this diastolic blood pressure, 5 out of 10 subjects had symptoms outside the range of appropriate values, and among these subjects, 4 subjects confirmed improvement once, and both improvements were confirmed There were 4 test subjects. Therefore, in this diastolic blood pressure, 80.0% of the subjects had symptoms and improved once, and 80.0% of the subjects had symptoms and improved twice.

  Next, in the abdominal circumference, when the first and seventh times were compared, the improvement of the abdominal circumference value of five subjects was confirmed, and when the second and seventh times were compared, the improvement of the six subjects could be confirmed. The improvement of 5.5 people was confirmed. Furthermore, in this abdominal circumference, 7 out of 10 subjects have symptoms higher than the appropriate value, and among these subjects, 5 subjects have confirmed improvement once, and those who have confirmed improvement twice. There were 5 people. Therefore, in this abdominal circumference, 71.4% of subjects had symptoms and improved once, and 71.4% of subjects had symptoms and improved twice.

  In addition, in AST (GOT), when the first and seventh times were compared, improvement in the AST (GOT) value in the blood of three subjects was confirmed, and when the second and seventh times were compared, two subjects were compared. The improvement was confirmed, and when these were averaged, the improvement of 2.5 people was confirmed. Furthermore, in this AST (GOT), 1 out of 10 subjects has a symptom higher than the appropriate value, and among these subjects, 0 subjects have confirmed improvement once, and both improvements can be confirmed twice. There were 0 subjects.

  And in ALT (GPT), when the first time and the seventh time were compared, the improvement of the ALT (GPT) value in the blood of three subjects was confirmed, and when the second time and the seventh time were compared, four subjects The improvement was confirmed, and when these were averaged, the improvement of 3.5 people was confirmed. Furthermore, in this ALT (GPT), 3 out of 10 subjects had symptoms higher than the appropriate value, and 3 of these subjects were able to confirm improvement once, and both improvements could be confirmed. There was one subject. Therefore, in this ALT (GPT), 100.0% of subjects had symptoms and improved once, and 33.3% of subjects had symptoms and improved twice.

  Next, in γ-GTP (γ-GT), the first time and the seventh time were compared. As a result, the improvement of the γ-GTP (γ-GT) value in the blood of four subjects was confirmed. As a result, the improvement of 3 subjects was confirmed, and when these were averaged, the improvement of 3.5 people was confirmed. Further, in this γ-GTP (γ-GT), 3 out of 10 subjects have symptoms higher than the appropriate value, and one of these subjects has confirmed improvement once, and the improvement is 2 One subject was able to confirm both times. Therefore, in this γ-GTP (γ-GT), 33.3% of the subjects had symptoms and improved once, and 33.3% of the subjects had symptoms and improved twice.

  In addition, in the total cholesterol, when comparing the first time and the seventh time, the improvement of the total cholesterol level in the blood of the four subjects can be confirmed, and when comparing the second time and the seventh time, the improvement of the five subjects can be confirmed. When these were averaged, improvement of 4.5 persons could be confirmed. Furthermore, in this total cholesterol, 4 subjects out of 10 subjects have symptoms higher than the appropriate value, and among these subjects, 4 subjects confirmed improvement once, and subjects who confirmed improvement twice. There were two people. Therefore, in this total cholesterol, 100.0% of subjects had symptoms and improved once, and 50.0% of subjects had symptoms and improved twice.

  And in HDL cholesterol, when comparing the first time and the seventh time, the improvement of the HDL cholesterol level in the blood of six subjects can be confirmed, and when comparing the second time and the seventh time, the improvement of five subjects can be confirmed. When these were averaged, the improvement of 5.5 persons was confirmed. Furthermore, with this HDL cholesterol, 2 out of 10 subjects have symptoms lower than the appropriate value, and among these subjects, one subject has confirmed improvement once, and the subject has confirmed improvement twice. There were 0 people. Therefore, with this HDL cholesterol, 50.0% of subjects had symptoms and improved once, and 0.0% of subjects had symptoms and improved twice.

  Next, in the case of triglycerides, when the first time and the seventh time were compared, it was confirmed that the neutral fat level in the blood of 9 subjects was confirmed, and when the second time and the seventh time were compared, the improvement of 8 subjects was confirmed. It can be confirmed, and when these are averaged, an improvement of 8.5 persons can be confirmed. Furthermore, in this neutral fat, 5 subjects out of 10 subjects had symptoms higher than the appropriate value, and among these subjects, 4 subjects were able to confirm the improvement once, and the improvement was confirmed twice. There were 3 subjects. Therefore, in this neutral fat, 80.0% of the subjects had symptoms and improved once, and 60.0% of the subjects had symptoms and improved twice.

  Moreover, in the case of free fatty acids, the first time and the seventh time were compared, and the improvement of the free fatty acid level in the blood of 7 subjects was confirmed. The second time and the seventh time were compared, and the improvement of 7 subjects was confirmed. When these were averaged, an improvement of 7.0 was confirmed. Furthermore, in this free fatty acid value, 4 subjects out of 10 subjects had symptoms higher than the appropriate value, and among these subjects, 4 subjects were able to confirm the improvement once, and the improvement was confirmed twice. There was one subject. Therefore, with this free fatty acid, 100.0% of subjects had symptoms and improved once, and 25.0% of subjects had symptoms and improved twice.

  And in the case of uric acid, the first time and the seventh time were compared, and the improvement of the uric acid level in the blood of 8 subjects was confirmed. The second time and the seventh time were compared. An average of 7.5 people confirmed improvement. Furthermore, in this uric acid, 4 out of 10 subjects had symptoms higher than the appropriate value, and among these subjects, 4 subjects confirmed improvement once, and subjects who confirmed improvement twice. There were two people. Therefore, in this uric acid, 100.0% of subjects had symptoms and improved once, and 50.0% of subjects had symptoms and improved twice.

  Next, in the case of blood glucose, when comparing the first time and the seventh time, the improvement of the blood sugar level in the blood of one subject can be confirmed, and when comparing the second time and the seventh time, the improvement of four subjects can be confirmed. On average, the improvement of 2.5 people was confirmed. Furthermore, with this blood glucose, 0 out of 10 subjects were in a state with symptoms higher than the appropriate value.

  In insulin, the first time and the seventh time were compared, and the improvement in insulin levels in the blood of two subjects was confirmed. The second time and the seventh time were compared, and four subjects were confirmed to be improved. On average, an improvement of 3.0 people was confirmed. Furthermore, with this insulin, 2 out of 10 subjects have symptoms that are higher than the appropriate value, and among these subjects, 2 subjects have confirmed improvement once and 2 subjects have confirmed improvement twice. There were 0 people. Therefore, in this insulin, 100.0% of subjects had symptoms and improved once, and 0.0% of subjects had symptoms and improved twice.

  Furthermore, in the case of adiponectin, when the second time and the seventh time were compared, it was confirmed that the adiponectin level in the blood of four subjects was improved.

(result)
From the above, a decrease in body weight of 10.5 / 16 persons could be confirmed in the first intake group, and a decrease in body weight of 4/10 persons could be confirmed in the second intake group. As a result, it was confirmed that the intake of about 10 male tablets and 8 female tablets per day of H tablets had an effect of reducing body weight.

  In addition, it was possible to confirm the displacement of the systolic blood pressure of 14/16 persons to the appropriate value in the first intake group, and the displacement of the 4.5 persons / 10 person to the appropriate value of the systolic blood pressure in the second intake group. did it. As a result, it was confirmed that the intake of at least about 3 males and females per day each of the H tablets had an effect of adjusting the systolic blood pressure to an appropriate value, and 10 males and 8 females per day of these H tablets. It was recognized that the effect of adjusting the systolic blood pressure to an appropriate value was obtained by ingesting about the tablet level.

  Furthermore, the displacement of 13/16 people to the appropriate value of diastolic blood pressure can be confirmed in the first intake group, and the displacement of 4.5 people / 10 people to the appropriate value of diastolic blood pressure can be confirmed in the second intake group. did it. As a result, it was confirmed that the intake of about 10 male tablets and about 8 female tablets per day of H tablets had an effect of adjusting the diastolic blood pressure to an appropriate value. Therefore, from the results of these systolic blood pressure and diastolic blood pressure, it was confirmed that there was an effect of adjusting blood pressure to an appropriate value by taking about 10 male tablets and 8 female tablets per day of H tablets.

  In addition, a decrease in the abdominal circumference value of 9.5 / 16 persons was confirmed in the first intake group, and a decrease in the abdominal circumference value of 5.5 / 10 persons was confirmed in the second intake group. As a result, it is recognized that there is an abdominal circumference reducing effect by taking at least about 3 tablets of men and women per day of H tablets, and about 10 tablets of men and about 8 tablets of women per day of H tablets, It was observed that there was a more abdominal circumference reduction effect.

  Furthermore, a decrease in AST (GOT) value of 11/16 persons was confirmed in the first intake group, and a decrease in AST (GOT) value of 2.5 / 10 persons was confirmed in the second intake group. As a result, it was confirmed that the intake of about 10 male tablets and about 8 female tablets per day of H tablets had an effect of decreasing the AST (GOT) value.

  In addition, a decrease in the ALT (GPT) value of 10.5 / 16 persons was confirmed in the first intake group, and a decrease in the ALT (GPT) value of 3.5 persons / 10 persons was confirmed in the second intake group. . As a result, it was confirmed that an intake of about 10 male tablets and about 8 female tablets per day of H tablets had an effect of decreasing the ALT (GPT) value.

  Furthermore, a decrease in the γ-GTP (γ-GT) value of 10/16 people in the first intake group could be confirmed, and a γ-GTP (γ-GT) value of 3.5 / 10 in the second intake group. Decrease was confirmed. As a result, it was confirmed that γ-GTP (γ-GT) value was decreased by taking about 10 male tablets and 8 female tablets per day.

  Moreover, the decrease of the total cholesterol value of 10.5 / 16 people was confirmed in the first intake group, and the decrease of the total cholesterol value of 4.5 / 10 people was confirmed in the second intake group. As a result, it was recognized that the intake of about 10 male tablets and about 8 female tablets per day of H tablets had an effect of reducing the total cholesterol level.

  Furthermore, an increase in the HDL cholesterol level of 4.5 / 16 persons could be confirmed in the first intake group, and an increase in the HDL cholesterol level of 5.5 / 10 persons could be confirmed in the second intake group. As a result, it was confirmed that the intake of about 3 tablets each of males and females per day of H tablets had an effect of increasing HDL cholesterol levels.

  Moreover, the decrease of the triglyceride value of 7/16 persons could be confirmed in the first intake group, and the decrease of the neutral fat value of 8.5 persons / 10 persons could be confirmed in the second intake group. As a result, it was confirmed that the ingestion of about 3 tablets each of males and females per day of H tablets had an effect of reducing the neutral fat level.

  Furthermore, a decrease in the free fatty acid value of 8.5 / 16 persons was confirmed in the first intake group, and a decrease in the free fatty acid value of 7/10 persons was confirmed in the second intake group. As a result, it was confirmed that the intake of about 3 tablets each of males and females per day of H tablets had an effect of reducing the free fatty acid level.

  In addition, a decrease in uric acid value of 9.5 / 16 people was confirmed in the first intake group, and a decrease in uric acid value of 7.5 / 10 subjects was confirmed in the second intake group. As a result, it was confirmed that the intake of about 3 tablets each of males and females per day of H tablets had a uric acid level reducing effect.

  Furthermore, in the first intake group, it was confirmed that the blood glucose level of 11/16 persons was shifted to an appropriate value, and in the second intake group, the shift of the blood sugar level of 2.5 persons / 10 persons to an appropriate value was confirmed. . As a result, it was confirmed that the intake of about 10 male tablets and 8 female tablets per day of H tablets had an effect of improving blood glucose levels.

  Moreover, the improvement of the hemoglobin A1c value of 7/16 persons could be confirmed in the first intake group, and the improvement of the hemoglobin A1c value could not be confirmed in the second intake group. As a result, it was confirmed that the intake of about 10 male tablets and about 8 female tablets per day of H tablets had an effect of improving the hemoglobin A1c value.

  Furthermore, the improvement of the insulin value of 9/16 persons was confirmed in the first intake group, and the improvement of the insulin value of 3/10 persons was confirmed in the second intake group. As a result, it was confirmed that an intake of about 10 male tablets and about 8 female tablets per day of H tablets had an action to improve insulin levels.

  Further, in the comparison between the second time and the seventh time, an increase in the adiponectin level of 10/16 people was confirmed in the first intake group, and an increase in the adiponectin level of 4/10 people was confirmed in the second intake group . As a result, it was confirmed that the intake of at least about 3 tablets each of males and females per day of H tablets had an effect of increasing adiponectin levels, and that the intake of about 10 males and 8 females per day of these H tablets It was confirmed that the adiponectin level increased more.

  As a result, by ingesting H tablets containing Elcampure extract powder, the effect of reducing body weight, the effect of adjusting blood pressure to an appropriate value, the abdominal circumference value reducing effect, ALT (GPT) after intake compared to before intake Value reducing action, γ-GTP (γ-GT) value reducing action, total cholesterol value reducing action, HDL cholesterol value increasing action, neutral fat value reducing action, uric acid value reducing action, blood glucose level improving action, hemoglobin A1c value It was found that each of an improving action, an insulin level improving action and an adiponectin level increasing action can be expected.

  Therefore, the H tablet contains ALT (GPT), γ-GTP (γ-GT), total cholesterol, HDL cholesterol, neutral fat, uric acid, blood sugar, hemoglobin A1c in blood that changes due to visceral fat accumulation as described above. Since it has been confirmed that various numerical values such as insulin and adiponectin are improved, it seems to have an inhibitory action, for example, a preventive action and an improvement action on the complex disease caused by this built-in fat accumulation, so-called metabolic syndrome It is done. That is, this H-tablet can be used as a disease-suppressing composition due to excess energy, in other words, a composition that suppresses excess energy-based disease.

  Here, the metabolic syndrome is a lifestyle-related disease mainly caused by visceral fat accumulation, that is, an accumulation state such as obesity, lipoprotein abnormality, high blood pressure, and high blood sugar. Furthermore, lipoprotein abnormalities include hypertriglyceridemia, low HDL cholesterolemia, hypercholesterolemia, and the like, and hyperglycemia is closely related to insulin resistance, serum free fatty acid, or elevated serum glucose level.

  And by preventing and improving the above-mentioned metabolic syndrome, by preventing and improving arteriosclerosis, respiratory diseases such as sleep apnea syndrome, neutral fat in the liver, fatty liver or cholelithiasis due to increased cholesterol, Cerebrovascular disorders such as cerebral infarction and cerebral hemorrhage, and ischemic heart diseases such as angina pectoris and myocardial infarction can be prevented or improved.

  Specifically, hypertension and hyperglycemia develop on the basis of visceral fat accumulation due to excess energy due to an increase in free fatty acids, abnormal adipocytokine secretion, an increase in insulin resistance, and an increase in blood glucose (serum glucose). At the same time, on the basis of visceral fat accumulation due to excess energy, fatty liver develops due to an increase in free fatty acids and an increase in hepatic neutral fat synthesis. Protein abnormalities develop.

Claims (8)

A composition for improving insulin resistance, comprising at least one of elcampure and an extract of elcampule and having an insulin resistance improving action. A composition for increasing adiponectin, comprising at least one of elcampure and an extract of elcampure, and having an adiponectin increasing action. A composition for improving hemoglobin A1c, comprising at least one of elcampure and an extract of elcampure, and having hemoglobin A1c improving action. A composition for improving blood glucose level, comprising at least one of Elcampure and an extract of Elcampure, and having a blood glucose level improving action. A composition for reducing uric acid level, comprising at least one of Elcampure and an extract of Elcampure and having a uric acid level-reducing action. A composition for improving liver function, comprising at least one of Elcampure and an extract of Elcampure, which has an effect of improving liver function. A composition for reducing abdominal circumference value, comprising at least one of Elcampure and an extract of Elcampure and having an abdominal circumference reducing action. A composition for reducing body weight, comprising at least one of Elcampure and an extract of Elcampure, and having a weight-reducing action.